Navigation Links
Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Date:12/11/2013

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced dosing of the first patients in its two Phase 3 trials of OTO-201 for the treatment of pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. OTO-201 is Otonomy's proprietary, sustained-exposure otic formulation of the antibiotic ciprofloxacin.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

The two identical, prospective, randomized, double-blind, sham-controlled Phase 3 studies are expected to enroll a combined total of approximately 500 subjects, ages 6 months to 12 years old, across 60 trial sites in the United States and Canada. The primary endpoint of the studies is the effectiveness of OTO-201 as measured through day 15 by the cumulative proportion of study treatment failures, which is defined as the presence of otorrhea (drainage) or use of antibiotic rescue medication. Completion of patient enrollment is expected during the second quarter of 2014.

"Following tube placement surgery, we frequently see parents of these very young patients struggle to comply with repeat administration of ear drops which is important to prevent post-operative complications," said pediatric otolaryngologist, Eric A. Mair, M.D., of Charlotte Eye, Ear, Nose & Throat Associates. "The potential to administer a full course of antibiotics with a single dose given during the procedure would be an attractive treatment option for patients, parents and physicians."

Added David A. Weber, Ph.D., president and CEO of Otonomy, "Initiating the two registration studies for O
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Menieres Disease
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. Otonomy Completes $45.9 Million Series C Equity Financing
4. S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD
5. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
6. Summit Yields One-of-a-Kind Opportunity To Reduce Prescription Drug Overdoses
7. CLAAD Warns of Increase in Prescription Drug Overdoses
8. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
9. As Prescription Painkiller Overdoses Mount, Researchers Outline Effective Approaches to Curb Epidemic
10. First Interim Analysis Of NW Bios Phase III GBM Trial Triggered By Reaching Required Number Of "Events"
11. Varian Medical Systems Schedules First Quarter FY2014 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...
... Oct. 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. ... China-based advanced in-vitro diagnostic ("IVD") company, today announced that ... approved the Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma ... as a companion diagnostic test for the use of ...
Cached Medicine Technology:Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... on in Chicago at Grant Park. The festival will end on Sunday, August ... to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma Applied ... can be accessed by visiting http://www.curemeso.org/store . , “Our new store features ... part: whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to ... it comes time to cook the next meal, making July the most appropriate to ... best grilling tips and recipes. , Make the next cookout different than the ones ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... rise in Britain last year with ethnic South Asians//, ... ,According to figures released by Britain's Health Protection ... TB cases in Britain, with 8,113 cases in 2005 ... of cases, 38 percent, was reported among people from ...
... of twenty four new drugs to combat HIV infection ... are plenty.// But the crux of the issue is the ... life expectancy by almost 24 years comes tagged with a ... a Cornell/Johns Hopkins/Harvard/Boston University research team analyzed the costs ...
... on mercury based flu vaccines given to pregnant women// and ... . This decision was made due to a vaccine shortage ... vaccine is manufactured by Sanofi pasteur, and the governor Arnold ... production to meet the state's need. ,The waiver was ...
... kits well past the expiry date , used to screen ... infections was found during raids conducted at Calcutta from ... company Monozyme India which had several contracts with the state ... forcibly calling back kits that have been already dispatched by ...
... of dengue, later confirmed positive for the fever, taking the ... ,Nearly 31 deaths have been confirmed with the ... of Health (NIH) has reiterated via a press release that ... in from all over Pakistan which is being tested quickly ...
... with low level of folic acid increases the risk of ... Research. ,This investigation carried out by scientists at ... disease and also how to prevent it. This research was ... which, they had shown how folate-rich diets offer protection against ...
Cached Medicine News:Health News:Low Folate Diet increases Colorectal Cancer risk 2
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
... Tm Bioscience introduces the Tag-It™ Cystic ... for cystic fibrosis genotyping. With validated performance ... assay will provide superior mutation coverage for ... aid to diagnosis in newborns. ,The ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: